We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Novel Diagnostic Assay Platform to Fasten Response Time to Emerging Pandemic Situations

By LabMedica International staff writers
Posted on 07 Feb 2023
Print article
Image: A collaborative project aims to deliver an innovative diagnostic platform for fast pandemic responsiveness (Photo courtesy of Clickmer)
Image: A collaborative project aims to deliver an innovative diagnostic platform for fast pandemic responsiveness (Photo courtesy of Clickmer)

The COVID-19 pandemic brought about a health crisis that highlighted severe fragilities within the healthcare sector, including lack of preparedness. In order to reduce vulnerability to future pandemics, there is a need for a large-scale, coordinated and comprehensive health response. Now, a new project aims to establish a diagnostic assay platform that can enable a faster response time during emerging pandemics.

A collaboration project, InfektoFlex, launched by Clickmer Systems (Manchester, UK) and Fraunhofer IMS (Duisburg, Germany) has received a EURO 1.1 million grant to develop an innovative diagnostic platform for fast pandemic responsiveness. The project which is due to commence in spring 2023 aims to establish a novel diagnostic assay platform that can enable a fast response time towards emerging pandemic situations. In the collaboration, Clickmers will be being combined with optical nanosensors, to develop a diagnostic assay platform with superior sensitivity and specificity having a faster response time for the detection of societal relevant emerging pathogens. Clickmers are synthetic antibody analogues that can bind to targets with high specificity and affinity. Optical nanosensors, which are fluorescent in near infrared light, qualify for low signal-to-noise ratio. Upon binding of a pathogen to the detection structure, the fluorescence of the nanosensor changes, thereby enabling measurement of the binding events.

“We are excited to launch the project InfektoFlex with Fraunhofer IMS. The platform will provide a more cost-efficient and time-saving solution, with a reduction in development costs through a more sustainable process compared to the commonly used ELISA assay systems (which require the usage of animal-derived antibodies),” said Dr. Ian Kavanagh, COO of APIS Assay Technologies. “Clickmer Systems will provide an adaptive and innovative diagnostic platform for pandemic responsiveness with higher reproducibility.”

Related Links:
Clickmer Systems 
Fraunhofer IMS 

Gold Supplier
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
New
Platinum Supplier
Automatic Nucleic Acid Extractor
GeneFlex 16n
New
Automated Electrolyte Analyzer
InSight
New
PCR Automatic Hybridization System
HybriSpot 12 Auto

Print article

Channels

Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more

Molecular Diagnostics

view channel
Image: The new assay enables accurate prognosis and detection data for those prone to esophageal cancer (Photo courtesy of Previse)

First-of-Its-Kind Test Helps Determine Future Risk of Esophageal Cancer

Esophageal cancer is among the most lethal cancers in the world and has a 20% five-year survival rate post-diagnosis. Barrett's esophagus is the sole precursor known and is a significant risk factor for... Read more

Immunology

view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more

Microbiology

view channel
Image: Sampling a single stool using multiple PCR panels can identify more pathogens rapidly (Photo courtesy of Pexels)

PCR Panels for Acute GI Infections Can Lower Costs, Hospitalization and Antibiotic Use

Acute gastroenteritis impacts adults across all age groups and incurs enormous healthcare expenses. Now, a new study comprising 40,000 hospital visits across various geographic locations has revealed that... Read more

Pathology

view channel
Image: Artificial intelligence predicts genetics of cancerous brain tumors in under 90 seconds (Photo courtesy of Michigan Medicine)

AI-Based Diagnostic Screening System Predicts Genetics of Cancerous Brain Tumors in 90 Seconds

The diagnosis and treatment of gliomas increasingly rely on molecular classification, as surgical benefits and risks vary depending on a patient's genetic makeup. Complete removal of the tumor can extend... Read more

Industry

view channel
Image: Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel (Photo courtesy of Roche)

Roche and Eli Lilly Collaborate on Innovative Blood Test for Early Diagnosis of Alzheimer's

Presently, obstacles to timely and precise diagnosis of Alzheimer's disease exist globally, resulting in as many as 75% of individuals exhibiting symptoms but lacking a formal diagnosis.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.